By Sabela Ojea
BridgeBio Pharma said it is fully financed to launch its cardiomyopathy treatment Attruby and read out its phase 3 clinical trials, which are fully enrolled.
Shares rose 8.6% to $31.58 in morning trading. The stock has, however, fallen 20% over the past 12 months.
The biotechnology company on Monday said that since the Food and Drug Administration approved Attruby in November, the treatment has been prescribed to 430 patients by 248 physicians.
BridgeBio Pharma also said it expects $105 million in regulatory milestones from acoramidis - sold under the brand name Attruby - approvals in Europe and Japan in the first half of the year, and that it received $500 million upon the FDA's drug acoramidis approval from royalty facility
Overall in the latest quarter, the company had $406 million in cash, BridgeBio Pharma added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 13, 2025 11:46 ET (16:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。